David Laskow-Pooley is a pharmacist with more than 35 years experience and proven track record in the pharmaceutical industry with the major international corporations including GlaxoSmithKline, Abbott and Amersham and emerging enterprises including OSI Pharmaceuticals. He has held senior posts in development, operations and general management, and involved in the development and launching of products in cancer (Tarceva® to treat lung cancer, the brachytherapy RAPID Strand® to treat prostate cancer), cardiovascular disease (Hytrin® to treat high blood pressure and enlarged prostate) and anti-infectives (Clarithromycin® to treat bacterial infections). He has created both spin-outs and start-ups during his career. David is Chairman and non-executive director of OBN, a membership organisation that supports and brings together the UK's emerging life sciences companies. Through this organisation and his other interests he has access to an extensive network of experts and specialist development companies. In March 2015 David was appointed to the Board of Seattle-based cancer immunotherapy company, TapImmune Inc, which is developing innovative vaccines for the treatment of cancer and infectious diseases.  David Laskow-Pooley is a pharmacist with more than 35 years experience and proven track record in the pharmaceutical industry with the major international corporations including GlaxoSmithKline, Abbott and Amersham and emerging enterprises including OSI Pharmaceuticals. He has held senior posts in development, operations and general management, and involved in the development and launching of products in cancer (Tarceva® to treat lung cancer, the brachytherapy RAPID Strand® to treat prostate cancer), cardiovascular disease (Hytrin® to treat high blood pressure and enlarged prostate) and anti-infectives (Clarithromycin® to treat bacterial infections). He has created both spin-outs and start-ups during his career. David is Chairman and non-executive director of OBN, a membership organisation that supports and brings together the UK's emerging life sciences companies. Through this organisation and his other interests he has access to an extensive network of experts and specialist development companies. In March 2015 David was appointed to the Board of Seattle-based cancer immunotherapy company, TapImmune Inc, which is developing innovative vaccines for the treatment of cancer and infectious diseases. 

FERMENTATION